Everest Medicines Receives $280 Million from Gilead Sciences for Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced that it has received a full upfront payment...
Company
Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors
China-based Akeso Biopharma (HKG: 9926) has entered into a strategic partnership with compatriot firm LaNova...
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has revealed that it has obtained an Emergency...
Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion Projects
China-based Huaren Pharmaceutical Co., Ltd is set to raise RMB 1.34 billion (USD 194.8 million)...
Everest Medicines Partners with Guangdong Provincial People’s Hospital in Kidney Disease Research
China-based Everest Medicines Ltd (HKG: 1952) has announced a comprehensive strategic partnership with Guangdong Provincial...
Sihuan Pharmaceutical’s KM501 Receives Clinical Trial Approval for HER2-Positive Tumors
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...
4B Technologies’ FB1001 Receives CDE Approval for Clinical Trials
China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from...
RemeGen’s RC48 Receives Two Clinical Trial Approvals for Breast Cancer Treatments
RemeGen Ltd (HKG: 9995) has announced the receipt of two clinical trial approvals for its...
Alphax Bio Raises Millions for Spatial Proteomics and Tumor Immune Microenvironment Research
Beijing-based Alphax Bio, a developer of immune-testing technologies, has reportedly raised “tens of millions” of...
Luye Pharma’s Lurbinectedin Gains Priority Review Status for SCLC Treatment
The Center for Drug Evaluation (CDE) website indicates that China-based Luye Pharma Group’s (HKG: 2186)...
Guangdong Zhongsheng’s RAY1216 Receives Conditional Approval for COVID-19 Treatment
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received conditional...
Hengrui Pharmaceuticals’ HRS-5965 Receives NMPA Approval for Clinical Study in Hemolytic Anemia
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval...
Sunshine Guojian Completes Patient Enrollment for SSGJ-611 Phase II Study in Atopic Dermatitis
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...
Henlius Biotech’s Serplulimab Accepted for EMA Review for ES-SCLC Treatment
Shanghai Henlius Biotech (HKG: 2696) has announced that the European Medicines Agency (EMA) has accepted...
Sino Biopharmaceutical’s F-star Therapeutics Signs Second Licensing Deal with Takeda
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a second licensing agreement between its recently acquired...
AstraZeneca’s Calquence Receives Conditional Approval in China for MCL
AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received conditional market approval in China...
Biohaven Acquires Global Rights for Dual TYK2/JAK1 Inhibitor BHV-8000 from Highlightll
US-based Biohaven Ltd. (NYSE: BHVN) has announced the acquisition of global rights, excluding China regions,...
Hinova Pharmaceuticals’ HC-1119 NDA Accepted for Review by NMPA
Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the New Drug Application (NDA)...
Boehringer Ingelheim Initiates Phase III FIBRONEER Studies for PDE4B Inhibitor BI 1015550
German pharmaceutical giant Boehringer Ingelheim (BI) has announced the first patient enrollments in the Phase...
Grand Pharmaceutical Group Reports 15.1% Revenue Growth in 2022 Financials
China-based Grand Pharmaceutical Group Limited (HKG: 0512) published its 2022 financials, reporting revenues of HKD...